New heart failure drug MK-2828 put through drug interaction test
NCT ID NCT07431866
First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This completed Phase 1 trial in 41 healthy adults tested whether multiple doses of MK-2828, a potential heart failure treatment, affect how the body processes rosuvastatin and furosemide. The goal was to check for drug interactions that could impact future dosing. The study provides early safety and interaction data but does not test MK-2828's effectiveness for heart failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MK-2828
- What this could lead to
- If successful, this study could help determine safe dosing of MK-2828 alongside common heart failure medications.
- What could go wrong
- This is an early-stage drug interaction study in healthy people, not a treatment trial. Results may not predict effectiveness or safety in heart failure patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit Inc ( Site 0001)
Daytona Beach, Florida, 32117, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test